{"id":928382,"date":"2026-01-19T08:10:34","date_gmt":"2026-01-19T13:10:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/"},"modified":"2026-01-19T08:10:34","modified_gmt":"2026-01-19T13:10:34","slug":"guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/","title":{"rendered":"Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform<\/b><\/p>\n<p class=\"bwalignc\"><i>Multi-year global collaboration will utilize Guardant liquid biopsy portfolio for the development of companion diagnostics for drug approvals<\/i><\/p>\n<p>PALO ALTO, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck\u2019s oncology portfolio using the Guardant Infinity\u2122 Smart platform.<\/p>\n<p>\nUnder the multi-year collaboration agreement, Guardant and Merck aim to:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nUse Guardant\u2019s portfolio of liquid and tissue biopsy tests as clinical trial enrolling assays in Merck\u2019s global clinical studies,<\/p>\n<\/li>\n<li>\nEvaluate opportunities to develop novel therapies using Guardant liquid biopsy tests as a companion diagnostic, and<\/p>\n<\/li>\n<li>\nPartner for global commercialization of drugs and companion diagnostics including in US, Asia-Pacific, UK and EU markets.<\/p>\n<\/li>\n<\/ul>\n<p>\n\u201cThis strategic collaboration allows us to bring the power of the Infinity Smart platform to some of the most important oncology programs in development today,\u201d said Helmy Eltoukhy, Guardant Health chairman and co-CEO. \u201cAs biomarkers become more central to therapy selection, our goal is to ensure that every trial has the molecular clarity needed to reach the right patients. This collaboration strengthens our shared commitment to rigor, scale, and faster development of life-changing cancer therapies.\u201d<\/p>\n<p><b>About Guardant Health<\/b><\/p>\n<p>\nGuardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fguardanthealth.com%2F&amp;esheet=54399563&amp;newsitemid=20260119596555&amp;lan=en-US&amp;anchor=guardanthealth.com&amp;index=1&amp;md5=f8f33bdc30f38de55b0b5db7f8ec7cbf\">guardanthealth.com<\/a> and follow the company on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fguardanthealth&amp;esheet=54399563&amp;newsitemid=20260119596555&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=75d1542e43cad2f9c704d0714ee60f9e\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FGuardantHealth&amp;esheet=54399563&amp;newsitemid=20260119596555&amp;lan=en-US&amp;anchor=X+%28Twitter%29&amp;index=3&amp;md5=8b4bd1184930c7f6ff9aa9db009be883\">X (Twitter)<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FGuardantHealth&amp;esheet=54399563&amp;newsitemid=20260119596555&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=2bf6638df63fc073ef926c0bc0e31f16\">Facebook<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health\u2019s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health\u2019s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operation\u201d and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health\u2019s views as of any date subsequent to the date of this press release.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260119596555r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260119596555\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260119596555\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Zarak Khurshid<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@guardanthealth.com\">investors@guardanthealth.com<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Meaghan Smith<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:press@guardanthealth.com\">press@guardanthealth.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Health Technology Clinical Trials Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260119596555\/en\/1330243\/3\/GuardantHealthLogo_TM_RGB-2C.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform Multi-year global collaboration will utilize Guardant liquid biopsy portfolio for the development of companion diagnostics for drug approvals PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211; Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck\u2019s oncology portfolio using the Guardant Infinity\u2122 Smart platform. Under the multi-year collaboration agreement, Guardant and Merck aim to: Use Guardant\u2019s portfolio of liquid and tissue biopsy tests as clinical trial enrolling assays in Merck\u2019s global clinical studies, Evaluate opportunities to develop &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-928382","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform Multi-year global collaboration will utilize Guardant liquid biopsy portfolio for the development of companion diagnostics for drug approvals PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211; Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck\u2019s oncology portfolio using the Guardant Infinity\u2122 Smart platform. Under the multi-year collaboration agreement, Guardant and Merck aim to: Use Guardant\u2019s portfolio of liquid and tissue biopsy tests as clinical trial enrolling assays in Merck\u2019s global clinical studies, Evaluate opportunities to develop &hellip; Continue reading &quot;Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-19T13:10:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260119596555r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform\",\"datePublished\":\"2026-01-19T13:10:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\\\/\"},\"wordCount\":658,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260119596555r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\\\/\",\"name\":\"Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260119596555r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-01-19T13:10:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260119596555r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260119596555r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/","og_locale":"en_US","og_type":"article","og_title":"Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform - Market Newsdesk","og_description":"Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform Multi-year global collaboration will utilize Guardant liquid biopsy portfolio for the development of companion diagnostics for drug approvals PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211; Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck\u2019s oncology portfolio using the Guardant Infinity\u2122 Smart platform. Under the multi-year collaboration agreement, Guardant and Merck aim to: Use Guardant\u2019s portfolio of liquid and tissue biopsy tests as clinical trial enrolling assays in Merck\u2019s global clinical studies, Evaluate opportunities to develop &hellip; Continue reading \"Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-19T13:10:34+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260119596555r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform","datePublished":"2026-01-19T13:10:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/"},"wordCount":658,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260119596555r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/","name":"Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260119596555r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-01-19T13:10:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260119596555r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260119596555r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-multi-year-strategic-collaboration-agreement-with-merck-to-develop-companion-diagnostics-and-commercialize-new-cancer-therapies-using-guardant-infinity-smart-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=928382"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928382\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=928382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=928382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=928382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}